Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
NCT07492693 · Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
NCT05236582 · Chemotherapy-induced Thrombocytopenia, Herombopag
NCT05864014 · Chemotherapy-Induced Thrombocytopenia
NCT06201663 · Chemotherapy-induced Thrombocytopenia, Solid Malignancy
NCT06099925 · Chemotherapy-induced Thrombocytopenia
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions